ProShares Ultra Silver ETF vs Cronos Group Inc — how do they compare? ProShares Ultra Silver ETF trades at $83.4, while Cronos Group Inc trades at $3.08 (market cap $1.14B). The key difference: Cronos Group Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | CRON | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $3.27 |
52-Week Low | $49.73 | $2.30 |
Market Cap | — | $1.14B |
Enterprise Value | — | $341.13M |
Signals from Pluang's Aura AI — not financial advice
ProShares Ultra Silver (AGQ) is trading at $76.86, up 5.97% on strong silver price momentum. The technical picture shows bullish moving averages with RSI indicating potential overbought conditions near resistance at $78. Recent news highlights AGQ's 9.39% surge as silver rallied 4-5%, though structural decay concerns persist for this 2x leveraged ETF.
The outlook remains volatile with silver price movements driving performance. Investment opportunity exists for bullish silver investors seeking amplified exposure, but structural decay and beta slippage present significant risks. AGQ consistently underperforms unlevered silver ETFs over time, making it suitable only for short-term tactical positions.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →